Aethlon Medical Announces HIV-AIDS Research Collaboration

Aethlon Medical Announces HIV-AIDS Research Collaboration

Business Wire - November 14, 2007

SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing medical devices to treat infectious disease, announced today it has initiated a research collaboration to study the in vitro effectiveness of the Aethlon Hemopurifier(R) to clear the Human Immunodeficiency Virus (HIV) from blood. The studies are being conducted through a collaboration established with ImQuest Biosciences, an infectious disease research organization based in Frederick, Maryland. The studies will document the rate at which the Aethlon Hemopurifier(R) captures infectious forms of HIV, including multi-drug resistant strains of the virus. The studies will also identify the capture rate of gp120, a toxin shed from the surface of HIV, which causes apoptosis (programmed cell death) of immune cells. Depletion of immune cells is the hallmark of AIDS. The goal of the studies will be to reinforce and expand upon HIV data previously obtained by Aethlon researchers. In HIV care, the Hemopurifier(R) is targeted to fill treatment voids of concern to all HIV-infected individuals.

-- As an adjunct therapy able to extend and enhance the benefit of antiviral drug regimens by inhibiting the proliferation of drug resistant HIV and immunosuppressive toxins.

-- As a non-drug therapy to maintain viral load suppression during structured treatment interruptions (STI), also known as "drug holidays".

About ImQuest Biosciences

ImQuest BioSciences, Inc. is a leading provider of biomedical research services, including anti-infective drug and vaccine discovery, complete preclinical therapeutic development, and the support and execution of basic initiatives in microbiology research. Addition information can be accessed online at www.imquest.com.

About Aethlon Medical

Aethlon Medical is the developer of the Hemopurifier(R), a first-in-class medical device to treat infectious disease. The Hemopurifier(R) addresses the largest opportunity in infectious disease, the treatment of drug and vaccine resistant viruses. Regulatory and commercialization initiatives in the United States are focused on bioterror threats, while international initiatives are directed towards naturally evolving pandemic threats, and chronic infectious disease conditions including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Collaborative studies to demonstrate utility of the Hemopurifier(R) are being conducted with researchers at the Government of India's National Institute of Virology (NIV), The Centers for Disease Control and Prevention (CDC), The United States Army Medical Research Institute of Infectious Diseases (USAMRIID), and The Southwest Foundation for Biomedical Research (SFBR). Aethlon recently demonstrated safety of the Hemopurifier(R) in a 24-treatment human study and is now conducting follow-on human studies at the Fortis Hospital in Delhi, India. The Company has also submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) related to advancing the Hemopurifier(R) as a broad-spectrum treatment countermeasure against category "A" bioterror threats. Additional information regarding Aethlon Medical and its Hemopurifier(R) technology can be accessed online at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

---

Contacts:

Aethlon Medical, Inc.

Jeff Richardson, Senior Director, Communications

858-459-7800 x302

jrichardson@aethlonmedical.com

071114
BW071115

Copyright © 2007 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .